# Single Arm Romiplostim to Prevent CIT

> **NCT07048249** · EARLY_PHASE1 · RECRUITING · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 26 (estimated)

## Conditions studied

- Ewings Sarcoma
- Chemotherapy Induced Thrombocytopenia

## Interventions

- **DRUG:** Romiplostim (AMG-531)

## Key facts

- **NCT ID:** NCT07048249
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-26
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07048249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07048249, "Single Arm Romiplostim to Prevent CIT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07048249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*